AstraZeneca PLC produced one of the world’s most widely used Covid-19 vaccines. As demand for the shot ebbs, the company is betting on tackling breast cancer and a different respiratory virus.
After the pandemic hit, the drugmaker poured resources into fighting Covid-19. It produced a vaccine and a drug, named Evusheld. The vaccine didn’t generate a profit, however, and its rollout faced a string of challenges including confusion over trial data, concerns about a rare side effect and delayed deliveries.
